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 BACKGROUND 
 A prolactinoma is a benign tumour of the pituitary gland 
that produces prolactin. In men, the most common symp-
toms of hyperprolactinaemia are decreased libido, erectile 
dysfunction and infertility. In addition, macroprolactino-
mas by their very size may press on surrounding structures 
causing headaches or loss of vision (bitemporal hemian-
opsia) from pressure on the cross-over of the optic nerves. 
Dopamine normally inhibits prolactin secretion, so fi rst-
line treatment of patients with prolactinoma is a dopamine 
D2-receptor agonist. 1 These drugs shrink the tumour and 
return prolactin levels to normal in approximately 80% of 
patients. However, standard treatment of prolactinoma 
increases dopaminergic activity and has the potential to 
exacerbate psychotic symptoms. Psychosis is associated 
with increased dopamine activity and is treated mainly 
with antipsychotic drugs that block dopamine D2 recep-
tors. Thus, prolactinoma and psychosis require treatments 
that oppose each other. 2 
 In some patients with prolactinoma and psychosis, it 
is diffi cult to achieve optimal balance between dopamine 
agonists and antagonists. In the present case report, we 
describe a psychotic patient with an inoperable prolac-
tinoma who was treated with several antipsychotic agents 
without the desired effect on his debilitating auditory hal-
lucinations. However, he did respond to additional cogni-
tive behavioural therapy (CBT). This case report is the fi rst 
to describe the option of additional CBT in the treatment 
of patients with prolactinoma and psychosis. Furthermore, 
the symptoms of this patient may provide some insight 
into the mechanisms underlying recurrent psychosis. 
Sensitisation may cause the enhancement or intensifi cation 
of a specifi c response to a drug following prior exposure to 
the same (or functionally similar) drug. This patient used 
cannabis for a long period before his fi rst psychotic symp-
toms appeared. Systemic administration of the psycho-
active ingredient in cannabis, Δ-9- tetrahydrocannabinol, 
increases fi ring of dopaminergic neurons in the midbrain. 3  4 
In our patient, the dopamine agonist medication may have 
triggered an already sensitised dopamine system leading to 
recurrent psychosis. 
 CASE PRESENTATION 
 A 33-year-old man was referred in 2008 to the Department 
of Early Psychosis of the Academic Medical Center in 
Amsterdam, the Netherlands. Four years earlier, a prolac-
tinoma had been discovered (macroprolactinoma 4×5 cm). 
Quinagolide (a dopamine agonist) was started to lessen 
tumour growth, but liquor leakage developed due to destruc-
tion of the skull base by the prolactinoma and shrinkage of 
the prolactinoma. This was complicated by meningitis in 
2005. Before the patient became ill he had been a computer 
programmer and had lived alone. He stopped working in 
2006. He had used cannabis from before age 15 until age 32 
(2007) on a daily basis. After a tumour debulking operation 
was performed in January 2007, quinagolide was restarted 
and slowly increased from 18.75 mg to 112.5 mg per day 
without liquor leakage. However, in March 2008 when the 
dose was increased to 112.5 mg, severe psychotic symp-
toms emerged for the fi rst time. The patient heard voices 
that ordered him not to shower, not to get off the couch, 
etc. If he did not listen, they administered a stinging pain, 
after which he immediately obeyed their commands. In 
2008 he started living with his mother because the voices 
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ordered him not to go to his own house. Two months 
later he was admitted involuntarily to a psychiatric ward 
because he had threatened his mother and his nieces and 
nephews with a knife. 
 INVESTIGATIONS 
 A structural MRI scan showed a large prolactinoma 
( fi gure 1 ). 
 DIFFERENTIAL DIAGNOSIS 
 Schizophrenia  ▶
 Substance-induced psychotic disorder.  ▶
 TREATMENT 
 In May 2008, quinagolide was stopped for 6 weeks with 
little effect on the severity of hallucinations but with mod-
est effect on persecutory delusions. Nonetheless, due to 
rising prolactin levels, quinagolide had to be restarted. The 
antipsychotic medication aripripazole 15 mg was started 
but discontinued after 2 months because of lack of effect 
on the psychotic symptoms. Antipsychotic medication 
was switched to quetiapine 800 mg and the commanding 
voices diminished to some extent but remained disturb-
ingly present. The delusional beliefs remitted completely. 
The time line of (treatment) events and clinical severity of 
the positive symptoms is depicted in  fi gure 2 . 
 Because the hallucinations persisted, antipsychotic 
medication was changed from quetiapine to leponex in 
February 2009 (up to 400 mg in April 2009, serum level 
of leponex was 0.50 mg/l). Later haloperidol (1 mg) was 
added but the voices remained even when the quinagolide 
was stopped for 4 weeks. 
 Cognitive therapy was started in May 2009. With com-
mand hallucinations, diminishing the power of the voices 
is important to lessen distress and decrease the likelihood 
of compliance. 5 – 7 At the start of therapy, the patient rated 
each of the three voices he was hearing as having 100% 
control over him, where 0 is no power and 100 is complete 
power. 
 The methods of collaborative empiricism and Socratic 
dialogue were used to engage the patient in question-
ing, challenging and restructuring his power beliefs. 
Collaborative empiricism is a cognitive therapy procedure 
in which the therapist formulates a hypothesis and then 
helps the patient test the validity of the hypothesis. With 
Socratic dialogue, guided discovery is used not to change 
a patient’s mind but to allow the patient to explore and 
refl ect on his thoughts and behaviours. Subsequently, we 
used behavioural tests to help the patient put these beliefs 
to empirical test. We discussed the fact that reducing the 
power of the voices involved disobeying the voices and 
experiencing what would happen. A hierarchy of less to 
more diffi cult commands to disobey was constructed. 
 Figure 1  MRI scan showing the large prolactinoma. 
BMJ Case Reports 2011; doi:10.1136/bcr.07.2010.3185 3 of 5
The easiest command was to switch on the light with the 
hand he wanted to use and the most diffi cult was to live 
in his own house. The patient was afraid that the voices 
would cause him pain if he disobeyed them. In addition, 
to improve the self-esteem of the patient, competitive 
memory training (COMET) 8 was employed. COMET is 
a technique that uses imagery of successful moments in 
life to counterbalance the negative emotions induced by 
voice content. Improved self-esteem can help the patient 
fi nd the courage to disobey the voices in behavioural 
experiments. 9 
 Starting with the least diffi cult command to disobey, 
the power of the voices was reduced after a few weeks 
from 100 to 70. Slowly the patient was able to stay for a 
few hours in his own house. To establish the lowest effec-
tive dose of antipsychotic medication with the least side 
effects, leponex was reduced to 200 mg and haloperidol 
was stopped without consequences in October 2009. Later 
on the patient also discussed professional training options 
with his job coach. He was able to sleep in his own house 
when his brother accompanied him. Because the patient 
insisted on trying one more antipsychotic to relieve him of 
the voices, medication was switched to olanzapine 10 mg 
in November 2009. 
 Meanwhile, the endocrinologist slowly increased 
quinagolide to 150 mg because his prolactin level was 
still too high. Psychotic symptoms increased. The patient 
also started hearing a fourth voice that told him to stop 
smoking or otherwise the voice would give him a heart 
attack. With the restart of leponex in December 2009, the 
additional psychotic symptoms swiftly disappeared but 
the fourth voice remained. The patient indicated that he 
did not want to and could not stop smoking and that he 
experienced intense fear and stress because of this voice. 
We therefore planned a behavioural experiment to test the 
credibility of the fourth voice. The patient scored the cred-
ibility of the threat at 30 on a scale of 0 (no credibility) to 
100 (no doubt). If the patient had a heart attack within a 
month, this would prove that the voice was able to give 
the patient a heart attack. If the patient did not have a heart 
attack, then the voice had no power to do as it claimed. 
After 2 weeks of smoking and no heart attack, the credibil-
ity of the voice was reduced to 20 and after a month to 1. 
At the end of 15 CBT sessions, the patient was able to stay 
in his own house alone and to work on his computer pro-
grams. The voices continued to be present but the patient 
was able to disregard their commands. Such an outcome is 
typical of that reported by Trower  et al 5 : reduced motiva-
tion to comply with voices leads to reduced distress and 
impact, but without changing the fundamental topogra-
phy of the voices (frequency, content, etc). 
 OUTCOME AND FOLLOW-UP 
 The Psychotic Symptom Rating Scales (PSYRATS) 10 was 
used to assess hallucinations before and after CBT treat-
ment. Haddock  et al 10 distinguished three factors on the 
PSYRATS auditory hallucinations rating scale: an emo-
tional characteristics factor (amount and degree of negative 
content of the voices, amount and intensity of distress), 
a physical characteristics factor (frequency, duration, loca-
tion and loudness of the voices) and a cognitive interpre-
tation factor (beliefs about voices, disruption of daily life 
and control). The scores on all three factors were decreased 
after treatment, with the strongest decrease in the cogni-
tive interpretation factor score ( fi gure 3 ). 
 At 6-month follow-up, the patient was still doing well. 
He was living in his own house and had started his own 
business writing computer programs. In addition, he was 
able to lose the weight he had gained as a side effect of the 
antipsychotic medication and to reduce his smoking habit. 
 Figure 2  Time line of (treatment) events and clinical severity of positive symptoms. 
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 DISCUSSION 
 The patient in this case report had two severe medical 
conditions that require oppositional treatment: prolac-
tinoma and psychosis. The psychotic symptoms started 
after an increase in the dosage of a dopamine D2-receptor 
agonist. It is not sure whether this medication was the 
sole cause of the psychotic disorder, since some symp-
toms were still present after a wash-out period of 6 weeks. 
However, the symptoms appeared quickly after the dos-
age of the dopamine D2-receptor agonist was increased 
and some persecutory beliefs became less severe during 
wash-out of the agonist. Nonetheless, the commanding 
auditory hallucinations remained although several antip-
sychotic medications were tried with adequate dosage 
and duration. 
 There have been a few case reports of iatrogenic psy-
chosis in patients treated with dopamine agonist thera-
pies for a prolactinoma. 11 – 13 An increase in dopaminergic 
activity in the mesolimbic area of the brain due to these 
medications has been suggested as the aetiology of such 
cases of psychosis. Several case reports have been pub-
lished describing patients with a prolactinoma and schizo-
phrenia, delineating the dilemma between treating the 
prolactinoma and treating the psychosis. Aripripazole has 
been suggested as the treatment of choice because of its 
effectiveness in treating the symptoms of schizophrenia 
while allowing the patient to maintain a normal prolactin 
level in the presence of a functional prolactinoma without 
the need for additional medications that could complicate 
treatment of the patient’s psychosis. 14 However, in our 
patient aripripazole was discontinued because of lack of 
effect on his psychotic symptoms. 
 We have to take into consideration that (1) the patient 
started using cannabis before age 15 and continued 
to use it on a daily basis until age 32 (cannabis abuse 
before age 15 is a known risk factor for schizophrenia 15 ); 
(2) the patient had multiple insults to his brain starting 
with a large prolactinoma extending to his frontal cor-
tex, followed by meningitis and then neurosurgery. The 
dopamine D2-receptor agonist may have been the tipping 
point in the dopamine disturbances already present prior 
to use of this medicine. 
 The reduced impact of the auditory hallucinations 
during CBT is supported by the revised dopamine 
hypothesis of Howes and Kapur. 16 They propose that 
the locus of dopamine dysregulation is primarily at the 
presynaptic dopaminergic control level and that this dys-
regulation is the ‘fi nal common pathway’ to psychosis. 
The abnormal release of dopamine leads to an aberrant 
assignment of salience to innocuous stimuli. It is argued 
that psychotic symptoms emerge over time as the indi-
vidual’s own explanation of the experience of aberrant 
salience. Psychosis is, therefore, aberrant salience driven 
by dopamine and fi ltered through the individual’s exist-
ing cognitive and sociocultural schemas, thus allowing 
the same chemical (dopamine) to have different clini-
cal manifestations in different cultures and different 
individuals. 16 
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